Brittany Shanice Williams LPC, NCC, CSC, M.S.

Recommended Articles

• Antibiotics for Cystic Fibrosis

  Cystic fibrosis damages the lungs, digestive system, and other organs in the body. It affects the cells producing mucus, sweat, and digestive juices. It is caused due to defect in a gene. This gene changes a protein responsible for movement of salts in and out of cells. As a result, thick, sticky...

• What Is an Auditory Hallucination?

  Auditory hallucinations are false perceptions of sound in the absence of an external stimulus. You basically hear voices talking to you or other noises or music, which others around you do not hear. It is a very common symptom among schizophrenics. As a percentage, about 70 percent of schizophrenic...

• Suicide Rates Are Rising in Those with Rheumatoid Arthritis

  While suicide is universally viewed as a massive problem that needs to be prevented, many don't realize that it is not only mental illnesses that can trigger this type of action. For those dealing with rheumatoid arthritis, suicide attempts are now at a higher rate than ever seen previously.Too much...

• To B3 or Not To B3: Is That the Question for Parkinson's Disease?

  Researchers haven’t discovered a cure or a way to mask the disease. However, finding a cure is a priority for many organizations, and researchers have uncovered several key things for treatment. What they have discovered, and what they continue to discover, is how to treat the different symptoms...

• Comparative Value of PARP Inhibitors is Lacking, According to ICER Report

  The Institute for Clinical and Economic Review, also known as ICER, is a non-profit organization that analyzes the value of new medical tests, treatments, and drugs approved by the U.S. Food and Drug Administration (FDA). The goal of ICER is to use the value of these innovations and develop reports...

• FDA Approves Baricitinib for Adults with Active Rheumatoid Arthritis

  On June 1st of 2018, the US Food and Drug Administration (FDA) approved Olumiant (Baricitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more TNF inhibitor therapies. “We are pleased to provide RA...